Vedolizumab Market Research Report
On Oct 29, the latest report "Global Vedolizumab Market 2025 by Manufacturers, Regions, Types and Applications, Forecast to 2031" from Global Info Research provides a detailed and comprehensive analysis of the global Vedolizumab market. The report provides both quantitative and qualitative analysis by manufacturers, regions and countries, types and applications. As the market is constantly changing, this report explores market competition, supply and demand trends, and key factors that are causing many market demand changes. The report also provides company profiles and product examples of some of the competitors, as well as market share estimates for some of the leading players in 2025.
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/2995555/vedolizumab
According to our (Global Info Research) latest study, the global Vedolizumab market size was valued at US$ 6010 million in 2024 and is forecast to a readjusted size of USD 9457 million by 2031 with a CAGR of 6.7% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Vedolizumab is a humanized monoclonal antibody targeting α4β7 integrin, which inhibits the interaction between this integrin and the gut-specific adhesion molecule MAdCAM-1, thereby preventing inflammatory lymphocytes from migrating to the gastrointestinal tract and reducing intestinal inflammation. It is primarily indicated for the treatment of moderate to severe active inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, and is administered via intravenous infusion. Vedolizumab offers tissue-specific action, minimizing systemic immunosuppression risks. In 2024, the global sales volume of vedolizumab reached 2.485 million doses, with an average price of 2,350 USD per dose.
Regional market landscape
The global vedolizumab market exhibits a distinct regional distribution, with North America accounting for 45.8%, Europe 33.2%, Asia-Pacific 14.5%, Latin America 4.3%, and the Middle East & Africa 2.2%. 90% administration is via intravenous infusion, and distribution channels are primarily hospitals and clinics at 87.5%, retail pharmacies 10.2%, and other channels 2.3%. These fixed regional and channel proportions directly affect production planning, inventory strategy, and market entry prioritization.
Key manufacturers and industry competition
The vedolizumab market is dominated by the originator Takeda, which maintains a strong global supply chain and production capacity, while biosimilar manufacturers such as Celltrion, Samsung Bioepis, and Sandoz have obtained regulatory approvals in certain regions and are gradually scaling production. Upstream, the supply chain includes recombinant antibody cell lines, culture media, downstream purification processes, and lyophilization excipients, with major CDMOs and raw material suppliers ensuring stable supply of the antibody and critical excipients. Downstream distribution is managed by hospitals, wholesalers, and distribution networks. Due diligence must assess upstream raw material and process stability, downstream concentration, and potential supply risks.
Technology trends and innovation direction
Current technological trends focus on optimizing antibody expression systems, improving process efficiency, enhancing stability of lyophilized and liquid formulations, and integrating digital process monitoring and process analytical technology (PAT). Biosimilar companies are improving downstream purification, increasing bioequivalence testing efficiency, and optimizing cold-chain logistics to reduce costs and improve product consistency, while also making minor innovations in administration convenience and patient adherence.
Policy and industry drivers
Regulatory policies and drug accessibility are primary drivers shaping the market, including biosimilar approval frameworks, pricing negotiations, reimbursement adjustments, patent and market exclusivity management, GMP certification of production facilities, and clinical safety monitoring requirements. These factors directly affect product launch speed, market share, and price elasticity, while policies encouraging domestic CDMO investment, import substitution, and supply chain stability can reshape industry competition.
Outlook
In the coming years, as multiple biosimilar manufacturers expand capacity and gain regulatory approvals, the market is expected to move toward diversified supply and increased pricing pressure, though regional supply shortages may intermittently occur due to raw material volatility or policy changes. For investors and acquirers, focus will shift from individual financial performance to robustness of upstream antibody supply, redundancy of critical excipient channels, stability of downstream distribution, and long-term quality and compliance systems, with firms demonstrating strength across these areas positioned to gain competitive advantage.
This report is a detailed and comprehensive analysis for global Vedolizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Vedolizumab market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Intravenous Infusion、 Injection Pen
Market segment by Application: Crohn's Disease、 Ulcerative Colitis、 Others
Major players covered: Takeda Pharmaceutical、 Fresenius Kabi
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vedolizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vedolizumab, with price, sales quantity, revenue, and global market share of Vedolizumab from 2020 to 2025.
Chapter 3, the Vedolizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vedolizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Vedolizumab the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Vedolizumab sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Vedolizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vedolizumab.
Chapter 14 and 15, to describe Vedolizumab sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vedolizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/2995555/vedolizumab
According to our (Global Info Research) latest study, the global Vedolizumab market size was valued at US$ 6010 million in 2024 and is forecast to a readjusted size of USD 9457 million by 2031 with a CAGR of 6.7% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Vedolizumab is a humanized monoclonal antibody targeting α4β7 integrin, which inhibits the interaction between this integrin and the gut-specific adhesion molecule MAdCAM-1, thereby preventing inflammatory lymphocytes from migrating to the gastrointestinal tract and reducing intestinal inflammation. It is primarily indicated for the treatment of moderate to severe active inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, and is administered via intravenous infusion. Vedolizumab offers tissue-specific action, minimizing systemic immunosuppression risks. In 2024, the global sales volume of vedolizumab reached 2.485 million doses, with an average price of 2,350 USD per dose.
Regional market landscape
The global vedolizumab market exhibits a distinct regional distribution, with North America accounting for 45.8%, Europe 33.2%, Asia-Pacific 14.5%, Latin America 4.3%, and the Middle East & Africa 2.2%. 90% administration is via intravenous infusion, and distribution channels are primarily hospitals and clinics at 87.5%, retail pharmacies 10.2%, and other channels 2.3%. These fixed regional and channel proportions directly affect production planning, inventory strategy, and market entry prioritization.
Key manufacturers and industry competition
The vedolizumab market is dominated by the originator Takeda, which maintains a strong global supply chain and production capacity, while biosimilar manufacturers such as Celltrion, Samsung Bioepis, and Sandoz have obtained regulatory approvals in certain regions and are gradually scaling production. Upstream, the supply chain includes recombinant antibody cell lines, culture media, downstream purification processes, and lyophilization excipients, with major CDMOs and raw material suppliers ensuring stable supply of the antibody and critical excipients. Downstream distribution is managed by hospitals, wholesalers, and distribution networks. Due diligence must assess upstream raw material and process stability, downstream concentration, and potential supply risks.
Technology trends and innovation direction
Current technological trends focus on optimizing antibody expression systems, improving process efficiency, enhancing stability of lyophilized and liquid formulations, and integrating digital process monitoring and process analytical technology (PAT). Biosimilar companies are improving downstream purification, increasing bioequivalence testing efficiency, and optimizing cold-chain logistics to reduce costs and improve product consistency, while also making minor innovations in administration convenience and patient adherence.
Policy and industry drivers
Regulatory policies and drug accessibility are primary drivers shaping the market, including biosimilar approval frameworks, pricing negotiations, reimbursement adjustments, patent and market exclusivity management, GMP certification of production facilities, and clinical safety monitoring requirements. These factors directly affect product launch speed, market share, and price elasticity, while policies encouraging domestic CDMO investment, import substitution, and supply chain stability can reshape industry competition.
Outlook
In the coming years, as multiple biosimilar manufacturers expand capacity and gain regulatory approvals, the market is expected to move toward diversified supply and increased pricing pressure, though regional supply shortages may intermittently occur due to raw material volatility or policy changes. For investors and acquirers, focus will shift from individual financial performance to robustness of upstream antibody supply, redundancy of critical excipient channels, stability of downstream distribution, and long-term quality and compliance systems, with firms demonstrating strength across these areas positioned to gain competitive advantage.
This report is a detailed and comprehensive analysis for global Vedolizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Vedolizumab market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Intravenous Infusion、 Injection Pen
Market segment by Application: Crohn's Disease、 Ulcerative Colitis、 Others
Major players covered: Takeda Pharmaceutical、 Fresenius Kabi
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vedolizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vedolizumab, with price, sales quantity, revenue, and global market share of Vedolizumab from 2020 to 2025.
Chapter 3, the Vedolizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vedolizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Vedolizumab the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Vedolizumab sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Vedolizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vedolizumab.
Chapter 14 and 15, to describe Vedolizumab sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vedolizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
